You are here

clinical trials

Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light

Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light

Endpoints

clinical trials

Flag link:

Intercept Pharma is One Step Closer to Filing for Approval of First NASH Treatment

Intercept Pharma is One Step Closer to Filing for Approval of First NASH Treatment

BioSpace

Intercept Pharmaceuticals

obeticholic acid

clinical trials

Flag link:

Higher dose of Pfizer-Lilly drug helps reduce back pain in study

Higher dose of Pfizer-Lilly drug helps reduce back pain in study

Yahoo/Reuters

chronic low back pain

clinical trials

opioid alternatives

Flag link:

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

Pharmaceutical Business Review

Boehringer Ingelheim

type 2 diabetes

clinical trials

Flag link:

Merck plans trio of Phase 3 Keytruda studies in prostate cancer

Merck plans trio of Phase 3 Keytruda studies in prostate cancer

BioPharma Dive

prostate cancer

clinical trials

Flag link:

Boehringer Ingelheim and IBM link up for blockchain-powered clinical trials in Canada

Boehringer Ingelheim and IBM link up for blockchain-powered clinical trials in Canada

Fierce Biotech

Boehringer Ingelheim

clinical trials

Flag link:

Interview: Clinical Trial Transparency Is Improving, Particularly Among Larger Companies

Interview: Clinical Trial Transparency Is Improving, Particularly Among Larger Companies

BioSpace

clinical trials

clinical trial transparency

Flag link:

Asco-GU – Bristol’s renal cancer lead looks to be short-lived

Asco-GU – Bristol’s renal cancer lead looks to be short-lived

EP Vantage

renal cell carcinoma

Bristol-Myers Squibb

clinical trials

Flag link:

It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial

It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial

Endpoints

Gilead Sciences

clinical trials

Flag link:

Here's Why Sage Therapeutics Gained 48.9% in January

Here's Why Sage Therapeutics Gained 48.9% in January

Motley Fool

SAGE Therapeutics

postpartum depression

clinical trials

Flag link:

Sangamo Sinks Most in a Decade as Gene-Editing Study Fizzles

Sangamo Sinks Most in a Decade as Gene-Editing Study Fizzles

Bloomberg

Sangamo BioSciences

clinical trials

Flag link:

Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD

Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD

Endpoints

Solid Biosciences

clinical trials

Duchenne Muscular Dystrophy

Flag link:

Rare pediatric PRV program not linked to uptick in new drugs starting trials, study finds

Rare pediatric PRV program not linked to uptick in new drugs starting trials, study finds

Forbes

clinical trials

priority review vouchers

pediatric rare diseases

Flag link:

Takeda's Hemophilia A Drug: New Data and a $155 Million Patent Infringement Settlement

Takeda's Hemophilia A Drug: New Data and a $155 Million Patent Infringement Settlement

BioSpace

clinical trials

Flag link:

MacroGenics touts a PhIII win in a head-to-head with best-seller Herceptin for metastatic breast cancer

MacroGenics touts a PhIII win in a head-to-head with best-seller Herceptin for metastatic breast cancer

Endpoints

metastatic breast cancer

clinical trials

Flag link:

Moderna announces dosing of first monoclonal antibody encoded by mRNA in clinical trial

Moderna announces dosing of first monoclonal antibody encoded by mRNA in clinical trial

Pharmaceutical Business Review

Moderna Therapeutics

clinical trials

chikungunya virus

Flag link:

Lilly and Incyte's Olumiant Hits the Mark in Two Phase III Atopic Dermatitis Trials

Lilly and Incyte's Olumiant Hits the Mark in Two Phase III Atopic Dermatitis Trials

BioSpace

atopic dermatitis

clinical trials

Flag link:

Upcoming events – Ascendis and Lilly hope for growth with pivotal data

Upcoming events – Ascendis and Lilly hope for growth with pivotal data

EP Vantage

clinical trials

pediatric growth hormone deficiency

Flag link:

Sylentis' dry eye drug misses primary goals in phase 3

Sylentis' dry eye drug misses primary goals in phase 3

Fierce Biotech

dry eye disease

clinical trials

Flag link:

First phase 3 data back Scynexis' new-class antifungal

First phase 3 data back Scynexis' new-class antifungal

Fierce Biotech

clinical trials

Flag link:

Pages